A Two-part, Single Dose, Randomized, Single Blinded, Placebo Controlled, Phase I Study to Assess the Safety and Pharmacokinetics of Oral MT1980 in Healthy Volunteers When Dosed in the Fasted State
Latest Information Update: 08 Nov 2022
At a glance
- Drugs MT 1980 (Primary)
- Indications Cognition disorders; Neurogenic inflammation
- Focus Adverse reactions
- Sponsors Monument Therapeutics
Most Recent Events
- 01 Nov 2022 Status changed from active, no longer recruiting to completed.
- 26 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2022 New trial record